scholarly journals Long-Term Therapy with Growth Hormone: Bringing Sagacity to SAGHE

2012 ◽  
Vol 97 (1) ◽  
pp. 81-83 ◽  
Author(s):  
Mark A. Sperling
Keyword(s):  
Growth Hormone ◽  
Term Therapy ◽  
Long Term Therapy

Restoration of gallbladder contractility after withdrawal of long-term octreotide therapy in acromegalic patients

1993 ◽  
Vol 129 (3) ◽  
pp. 207-212 ◽  
Author(s):  
Yi-Fan Shi ◽  
Xian-Feng Zhu ◽  
Alan G Harris ◽  
Jin-Xi Zhang ◽  
Jie-Ying Deng
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Term Therapy ◽  
Serum Growth Hormone ◽  
Factor I ◽  
Gallbladder Contractility ◽  
Octreotide Therapy ◽  
Long Term Therapy ◽  
Growth Hormone Suppression

We sought to examine how the discontinuation of octreotide in long-term octreotide-treated acromegalic patients affects the well-documented side-effect of cholelithiasis. In 14 acromegalic patients, serum growth hormone levels, insulin-like growth factor I levels and percentage of relative gallbladder contractility were measured prior to and after the discontinuation of octreotide. Compared to pretreatment values, the basal growth hormone and 5-h growth hormone profiles were 36% and 24%, and 60% and 56% at the end of 1 and 2 weeks, respectively. Octreotide was found to be eliminated completely from the serum within 3 days after its withdrawal. In all of six patients who did not develop gallstones, the percentage relative gallbladder contractility normalized within 1 week. In eight patients who developed gallstones, four of them had restoration of normal contractility within 2 weeks. Our results show that upon withdrawal of octreotide, gallbladder contractility returns to normal while growth hormone suppression persists for a longer period of time. Therefore, discontinuation of octreotide therapy may allow for the clearance of stagnated bile and hence decrease the incidence of cholelithiasis in acromegalic patients receiving long-term therapy.

Good response to long-term therapy with growth hormone in a patient with 9p trisomy syndrome: A case report and review of the literature

2015 ◽  
Vol 170 (4) ◽  
pp. 1046-1049 ◽  
Author(s):  
Ana Pinheiro Machado Canton ◽  
Mirian Yumie Nishi ◽  
Tatiane Katsue Furuya ◽  
Rosimeire Aparecida Roela ◽  
Alexander Augusto Lima Jorge
Keyword(s):  
Growth Hormone ◽  
Case Report ◽  
Term Therapy ◽  
Review Of The Literature ◽  
Long Term Therapy

scholarly journals Effects of Growth Hormone on Craniofacial Growth

2006 ◽  
Vol 76 (6) ◽  
pp. 970-977 ◽  
Author(s):  
Minayo Funatsu ◽  
Koshi Sato ◽  
Hideo Mitani
Keyword(s):  
Growth Hormone ◽  
Therapy Group ◽  
Untreated Group ◽  
Term Therapy ◽  
Craniofacial Growth ◽  
Gh Therapy ◽  
Facial Height ◽  
Long Term Therapy ◽  
Ramus Height

Abstract Objective: This study determined the effects of growth hormone (GH) therapy on craniofacial growth in idiopathic growth hormone deficiency (GHD). Materials and Methods: Fifty-seven patients (33 boys and 24 girls; age range 4.5 to 16.7 years) with GHD were investigated and categorized into three groups according to the duration of GH therapy: the untreated group, the short-term therapy group, and the long-term therapy group. Their lateral cephalometric radiographs were studied, and craniofacial measurements were assessed by age and sex by using matched standard deviation scores. Results: In the untreated group, the anterior cranial base, total facial height, maxillary length, mandibular total length, mandibular body length, and ramus height were smaller than the standard values. In comparison with the untreated group, the long-term therapy group had a significantly larger upper facial height (P < .05), maxillary length (P < .01), and ramus height (P < .01) measurements. Conclusions: Children who received long-term GH replacement therapy showed increased growth of the craniofacial skeleton, especially the maxilla and ramus. These findings suggest that GH accelerates craniofacial development, which improves occlusion and the facial profile.

Long-term growth hormone treatment in growth hormone deficient adults

1991 ◽  
Vol 125 (4) ◽  
pp. 449-453 ◽  
Author(s):  
Jens O. L. Jørgensen ◽  
Søren A. Pedersen ◽  
Leif Thuesen ◽  
Jørgen Jørgensen ◽  
Jens Møller ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Treatment ◽  
Normal Subjects ◽  
Hormone Treatment ◽  
Long Term Results ◽  
Term Therapy ◽  
Gh Therapy ◽  
Double Blind ◽  
Long Term Therapy

Abstract. Growth hormone treatment in GH-deficient adults has proved beneficial in recent short-term trials, but long-term results have not yet been reported. Thirteen GH-deficient adults (4 females, 9 males; mean (sem) age 26.4 (1.7) years), who had completed 4 months of GH therapy in a double-blind placebo-controlled cross-over study were followed, for further 16.1 (0.8) months of uninterrupted GH therapy in an open design. A significant mean increase of 1.3 cm in linear height was recorded, whereas body mass index remained unchanged. Mean muscle volume of the thigh, estimated by computerised tomography, increased significantly compared with that of the initial placebo period (p=0.01), and a slight decrease was recorded in adipose tissue volume of the thigh (p=0.10) and subscapular skinfold thickness (p=0.10). Still, the muscle to fat ratio of the thigh was significantly lower compared with that of normal subjects (72.6/27.4 vs 77.9/22.1) (p<0.01). The mean isometric strength of the quadriceps muscles increased significantly during long-term GH therapy (p<0.01), but remained lower compared with that of normal subjects (1.66 (0.10) vs 2.13 (0.11) Nm/kg body weight). Exercise capacity performed on a bicycle ergometer increased significantly after long-term therapy (p<0.05), but still did not reach the values seen in normal subjects (22.5 (3.4) vs 37.4 (4.2) watt · min · kg−1· No adverse reactions were recorded during long-term therapy and hemoglobin A1c remained unchanged. These data suggest that long-term GH replacement therapy in GH-deficient adults has beneficial effects on several physiological features which are subnormal in these patients.

Hepatitis-C Patients Have Reduced Growth Hormone (GH) Secretion Which Improves During Long-Term Therapy With Pegylated Interferon-α

2007 ◽  
Vol 102 (12) ◽  
pp. 2724-2731 ◽  
Author(s):  
Ursula Plöckinger ◽  
Denny Krüger ◽  
Alexandra Bergk ◽  
Viola Weich ◽  
Bertram Wiedenmann ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hepatitis C ◽  
Pegylated Interferon ◽  
Term Therapy ◽  
Interferon Α ◽  
Gh Secretion ◽  
Long Term Therapy

Non-islet-cell tumor associated with hypoglycemia in a child: Successful long-term therapy with growth hormone

1995 ◽  
Vol 127 (3) ◽  
pp. 403-407 ◽  
Author(s):  
Michael S.D. Agus ◽  
Lorraine E.Levitt Katz ◽  
Marta Satin-Smith ◽  
Anna T. Meadows ◽  
Ray L. Hintz ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Islet Cell ◽  
Islet Cell Tumor ◽  
Cell Tumor ◽  
Term Therapy ◽  
Long Term Therapy

QS213. Effects of Long-Term Therapy With Growth Hormone on Scarring in Severely Burned Pediatric Patients

2009 ◽  
Vol 151 (2) ◽  
pp. 292
Author(s):  
L.K. Branski ◽  
C.C. Finnerty ◽  
M.G. Jeschke ◽  
L.N. Hollins ◽  
N.L. Ranallo ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Pediatric Patients ◽  
Term Therapy ◽  
Long Term Therapy
Sign in / Sign up

Export Citation Format

Share Document